Xenon Pharmaceuticals Stock Forecast, Price & News

-0.40 (-2.11 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume96,059 shs
Average Volume172,780 shs
Market Capitalization$761.99 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive XENE News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Xenon Pharmaceuticals logo

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop FX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.57 out of 5 stars

Medical Sector

477th out of 2,099 stocks

Pharmaceutical Preparations Industry

234th out of 830 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

Is Xenon Pharmaceuticals a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Xenon Pharmaceuticals stock.
View analyst ratings for Xenon Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Xenon Pharmaceuticals?

Wall Street analysts have given Xenon Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Xenon Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Xenon Pharmaceuticals?

Xenon Pharmaceuticals saw a decline in short interest during the month of May. As of May 28th, there was short interest totaling 657,400 shares, a decline of 13.5% from the May 13th total of 759,600 shares. Based on an average trading volume of 154,700 shares, the days-to-cover ratio is presently 4.2 days. Currently, 1.8% of the company's stock are short sold.
View Xenon Pharmaceuticals' Short Interest

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Xenon Pharmaceuticals

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) posted its quarterly earnings data on Tuesday, May, 11th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.45) by $0.03. The biopharmaceutical company earned $4.36 million during the quarter, compared to analysts' expectations of $3.70 million. Xenon Pharmaceuticals had a negative trailing twelve-month return on equity of 18.84% and a negative net margin of 126.05%.
View Xenon Pharmaceuticals' earnings history

How has Xenon Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)?

Xenon Pharmaceuticals' stock was trading at $12.71 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, XENE stock has increased by 46.3% and is now trading at $18.60.
View which stocks have been most impacted by COVID-19

What price target have analysts set for XENE?

4 Wall Street analysts have issued 1 year price targets for Xenon Pharmaceuticals' stock. Their forecasts range from $25.00 to $28.00. On average, they expect Xenon Pharmaceuticals' share price to reach $26.00 in the next year. This suggests a possible upside of 39.8% from the stock's current price.
View analysts' price targets for Xenon Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the following people:
  • Dr. Simon N. Pimstone, CEO & Director (Age 53, Pay $811.28k)
  • Mr. Ian C. Mortimer C.M.A., CPA, M.B.A., MBA, CPA, CMA, Pres & CFO (Age 45, Pay $684.83k)
  • Ms. Jodi Regts M.B.A., B.A., MBA, VP of Corp. Affairs & Investor Relations
  • Ms. Shelley McCloskey, Sr. VP of HR (Age 61)
  • Dr. Robin P. Sherrington, Exec. VP of Strategy & Innovation (Age 60)
  • Dr. James R. Empfield, Exec. VP of Drug Discovery (Age 60)
  • Ms. Sheila M. Grant M.B.A., M.Sc., MBA, Sr. VP of R&D Operations
  • Dr. Christopher E. Von Seggern M.B.A., M.P.H., Ph.D., M.P.H. M.B.A, Chief Commercial Officer (Age 42)
  • Dr. Kenneth Sommerville, Interim Chief Medical Officer

Who are some of Xenon Pharmaceuticals' key competitors?

What other stocks do shareholders of Xenon Pharmaceuticals own?

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (8.50%), Bank of New York Mellon Corp (2.34%), Ghost Tree Capital LLC (2.08%), Point72 Asset Management L.P. (1.86%), Baker BROS. Advisors LP (1.83%) and Renaissance Technologies LLC (1.69%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab, Sherrington Robin and Simon N Pimstone.
View institutional ownership trends for Xenon Pharmaceuticals

Which institutional investors are selling Xenon Pharmaceuticals stock?

XENE stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Millennium Management LLC, Granite Point Capital Management L.P., Knott David M, Acadian Asset Management LLC, BlackRock Inc., Bank of Montreal Can, and BVF Inc. IL. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, and Sherrington Robin.
View insider buying and selling activity for Xenon Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Xenon Pharmaceuticals stock?

XENE stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Perceptive Advisors LLC, Suvretta Capital Management LLC, Lord Abbett & CO. LLC, Acuta Capital Partners LLC, Point72 Asset Management L.P., Tekla Capital Management LLC, and Citadel Advisors LLC.
View insider buying and selling activity for Xenon Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $18.60.

How much money does Xenon Pharmaceuticals make?

Xenon Pharmaceuticals has a market capitalization of $761.99 million and generates $32.17 million in revenue each year. The biopharmaceutical company earns $-28,840,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

How many employees does Xenon Pharmaceuticals have?

Xenon Pharmaceuticals employs 123 workers across the globe.

What is Xenon Pharmaceuticals' official website?

The official website for Xenon Pharmaceuticals is

Where are Xenon Pharmaceuticals' headquarters?

Xenon Pharmaceuticals is headquartered at 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]

This page was last updated on 6/13/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.